Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery
BioArctic, a Swedish biotechnology company renowned for its innovative approach
German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies
CatalYm, a German biotech company specializing in cancer immunotherapy, has
Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials
The field of cancer treatment is on the cusp of
UroGen Aims to Raise $107M to Advance Innovative Obesity and Bladder Cancer Therapies
Introduction Overview of UroGen: UroGen Pharma Ltd., headquartered in Princeton,
Marea Biotech Secures $190 Million for Heart Disease Research
Introduction Marea Biotech, a pioneering company in the biotech industry,
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
Forbion-Backed VectorY Therapeutics Raises $138M for ALS and Neurodegenerative Disease Research
VectorY Therapeutics, a biotechnology company based in Amsterdam, Netherlands, has
MOST POPULAR
